Alkem Laboratories Share Price Target 2025, 2026, 2030, 2040, 2050

Alkem Laboratories is an Indian medicine company. It makes many kinds of medicines like regular drugs, special medicines, health supplements, and APIs, and it is known for popular products like Clavam, Pan, Pan-D, and Taxim-O. The company makes medicines for everyday health problems such as infections, pain, heart issues, brain problems, stomach troubles, diabetes, and skin issues. It is one of the top pharma companies in India and sells its medicines in more than 40 countries, including a strong business in the U.S. It has 21 factories and strong research centres that help it make better and more affordable medicines.

What is Alkem Laboratories Ltd NSE: ALKEM?

Alkem Laboratories was established in 1973 in Patna, Bihar, by Samprada Singh. Today, its main office is in Mumbai, Maharashtra. It is a large Indian pharmaceutical company that makes a wide range of medicines, including regular tablets, capsules, and health supplements. It sells its products in India and in more than 40 countries. Its medicines are used for common health problems like infections, stomach issues, pain, heart diseases, brain-related problems, diabetes, and many other conditions.

Alkem Laboratories Share Price Target

Alkem Laboratories Share Price Target 2025

It is one of India’s top medicine-making companies. It began as a small company but slowly grew into a big global healthcare brand. In the beginning, it focused on making important and affordable medicines for Indian patients. As years passed, it added more products, improved its factories, and expanded to many countries. Its long journey shows its strong focus on good quality, honesty, and helping people stay healthy. In 2025, its share price target would be ₹6156, as per stock market analysts.

According to stock market analysts, its share price would be between ₹4491 to ₹6156 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	4491	6156

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4869	5673
February	4491	5318
March	4523	5092
April	5611	5299
May	4850	5400
June	4730	5118
July	4718	5112
August	4738	5480
September	5204	5591
October	5321	5648
November	5500	5868
December	5401	6156

Alkem Laboratories Share Price Target 2026

It makes many types of medicines for different health problems. It produces medicines for infections, stomach issues, pain, heart diseases, brain disorders, diabetes, skin problems, and many other conditions. This makes the company helpful for both simple and serious illnesses. Its products include branded generics, generic medicines, APIs, nutraceuticals, and modern drug delivery systems. Because it covers so many treatment areas, it supports doctors and patients with trusted and effective medicines. This wide range of products helps the company stay strong in India and other global markets. In 2026, its share price target would be ₹7652, as per stock market analysts.

According to stock market analysts, its share price would be between ₹5984 to ₹7652 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	5984	7652

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	5984	6314
February	6048	6447
March	6114	6587
April	6232	6615
May	6315	6689
June	6445	6788
July	6521	6957
August	6678	7115
September	6748	7225
October	6884	7356
November	7157	7541
December	7280	7652

Share Price Target 2027

It has many modern factories in India and other countries that make high-quality medicines. These plants produce tablets, capsules, syrups, powders, injections, and health supplements. Most factories are in India, but some are also in the United States. Many of these facilities follow strict international rules and are approved by global regulators. This ensures that its medicines are safe, effective, and consistent everywhere. In 2027, its share price target would be ₹9020, as per stock market analysts.

According to stock market analysts, its share price would be between ₹7541 to ₹9020 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	7541	9020

Share Price Target 2028

The company spends a lot of money and effort on creating new medicines and improving existing ones. Its research teams work on generics, special medicines, biosimilars, and advanced drug delivery systems. These improvements help make medicines safer, quicker to work, and easier for patients to use. R&D centres also help with global approvals and product launches. In 2028, its share price target would be ₹10430, as per stock market analysts.

According to stock market analysts, its share price would be between ₹8878 to ₹10430 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	8878	10430

Share Price Target 2029

It has many well-known and trusted brands in India. Some of its famous products include Clavam, Pan, Pan-D, and Taxim-O. These medicines are often prescribed for infections, acidity, and other common health problems. Doctors and patients trust these brands because they have been in the market for many years and offer reliable results. Its large product range includes medicines for both everyday health issues and serious diseases. Its strong brands show its understanding of patient needs and its commitment to giving safe and effective treatments. In 2029, its share price target would be ₹11840, as per stock market analysts.

According to stock market analysts, its share price would be between ₹10288 to ₹11840 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	10288	11840

Alkem Laboratories share price Target 2030

In India, it is one of the top-ranked pharmaceutical companies and is regularly placed among the top five in the Indian Pharma Market. It is especially strong in areas like anti-infectives, stomach medicines, pain relief, vitamins, and minerals. It has a large network of medical representatives and distributors who ensure its medicines reach cities, towns, and even villages. In 2030, its share price target would be ₹13290, as per stock market analysts.

According to stock market analysts, its share price would be between ₹11750 to ₹13290 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	11750	13290

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	11750	12000
February	11830	12241
March	11957	12388
April	12080	12457
May	12154	12587
June	12211	12668
July	12358	12785
August	12458	12898
September	12590	13000
October	12745	13147
November	12889	13258
December	12965	13390

Share Price Target 2040

It is active in over 40 countries around the world, including the United States, Latin America, Europe, Africa, Asia-Pacific, and Australia. This shows its ability to meet strict global standards and compete with big international pharma companies. It sells generic medicines, APIs, and speciality products in many countries. The company continues to expand with new product approvals, partnerships, and launches. In 2040, its share price target would be ₹22238, as per stock market analysts.

According to stock market analysts, its share price would be between ₹19984 to ₹22238 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	19984	22238

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	19984	20334
February	20074	20457
March	20142	20615
April	20321	20847
May	20458	20999
June	20651	21254
July	20778	21425
August	20887	21625
September	21321	21788
October	21554	21915
November	21784	22044
December	21854	22238

Share Price Target 2050

The company follows very strict rules while making, packing, and delivering medicines. Many of its factories meet international standards set by regulators like the U.S. FDA. This ensures that every medicine made by this company is safe, reliable, and effective. Quality checks happen at every stage to avoid mistakes and maintain trust among doctors and patients. This strong focus on quality has helped it to build a respected name in India and across the world. In 2050, its share price target would be ₹32382, as per stock market analysts.

According to stock market analysts, its share price would be between ₹30253 to ₹32382 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	30253	32382

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	30253	30665
February	30354	30789
March	30458	30958
April	30558	31084
May	30747	31147
June	30951	31357
July	31044	31557
August	31235	31778
September	31554	31956
October	31741	32000
November	31885	32141
December	32041	32382

Should I buy Alkem Laboratories stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	4491	6156
2026	5984	7652
2027	7541	9020
2028	8878	10430
2029	10288	11840
2030	11750	13290
2040	19984	22238
2050	30253	32382

It is a strong company with a good presence in India and other countries, and it has a solid range of medicines, which makes it a reliable long-term option. If you are looking to invest for the long term and can handle some ups and downs in the market, it could be a good stock to buy. However, if you are looking for quick profits or want something very safe with low risk, it might not be the best choice right now.

Alkem Laboratories earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	8,344	8,865	10,634	11,599	12,668	12,965	13,890
Expenses +	6,868	6,920	8,580	9,977	10,419	10,452	11,080
Operating Profit	1,476	1,945	2,054	1,622	2,249	2,512	2,810
OPM %	18%	22%	19%	14%	18%	19%	20%
Other Income +	102	230	146	101	186	494	492
Interest	65	59	52	107	112	122	129
Depreciation	253	275	304	310	299	357	379
Profit before tax	1,260	1,842	1,844	1,305	2,023	2,527	2,794
Tax %	9%	12%	9%	23%	10%	12%
Net Profit +	1,149	1,618	1,680	1,007	1,811	2,215	2,410
EPS in Rs	94.26	132.57	137.63	82.31	150.19	181.11	197.47
Dividend Payout %	27%	23%	25%	61%	27%	25%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
28.49	5.41	0.80%	36.57	5.77	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Alkem Laboratories Ltd	31.06	5.41	0.80%
Sun Pharmaceutical Industries Ltd	39.67	5.98	0.89%
Torrent Pharmaceuticals Ltd	67.27	16.94	0.84%
Cipla Ltd	23.17	3.90	1.06%

Is Alkem Laboratories stock good to buy? (bull case & bear case)

Bull Case:

• In Q2 FY26, Alkem made ₹40,010 million in revenue, which is 17.2% higher than last year, showing the company is growing.
• Its EBITDA rose 22.3% to ₹9,208 million, and EBITDA margin improved to 23.0%, meaning the company is earning money efficiently and managing costs well.
• Net profit increased 11.1% to ₹7,651 million, showing that the company is making more money from its sales.
• Domestic sales grew 12.4% and international sales increased nearly 30%, including strong growth in the U.S., which shows the company is growing in multiple markets.
• It keeps launching new products and gaining market share, especially in important areas like medicines for common illnesses, helping it grow more in the future.

Bear Case:

• Even though Q2 results are strong, the pharma industry is very competitive, and lower prices for generic drugs can reduce profits.
• Selling medicines internationally comes with risks like currency changes, foreign regulations, and slower demand, which can affect revenue and profits.
• In some past quarters, revenue grew, but profit didn’t grow as much, meaning higher sales don’t always mean more earnings.
• If costs increase or international demand slows down, the stock might not give strong returns.

Conclusion

It is a well-known Indian medicine company that makes many types of medicines, including regular drugs, special medicines, health supplements, and APIs, with popular products like Clavam, Pan, Pan-D, and Taxim-O. It grew from a small company in Patna to a global company with strong factories and research centres, selling its products in over 40 countries. Even though the medicine industry is competitive and selling abroad has some risks, its trusted brands, many products, and focus on quality make it a good choice for long-term investors.

FAQs